» Articles » PMID: 7528215

Identification of the Urokinase Receptor As an Adhesion Receptor for Vitronectin

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 1994 Dec 23
PMID 7528215
Citations 150
Authors
Affiliations
Soon will be listed here.
Abstract

Urokinase receptors, expressed on surfaces of many cell types, focus to the pericellular space plasminogen-dependent proteolysis important in matrix remodeling and cell movement. We now report that the urokinase receptor (uPAR) is also a high affinity (Kd < 30 nM) receptor for vitronectin. Recombinant uPAR binds vitronectin in the absence of urokinase, but vitronectin binding is promoted by concurrent receptor binding of either urokinase or fragments thereof containing its uPAR binding domain. Stable epithelial cell transfectants expressing membrane-anchored uPAR, but not cells expressing soluble uPAR, become strongly adhesive with altered morphology in the absence of urokinase. These observations identify a new class of vitronectin receptor and imply a duality in function for the receptor that intrinsically links matrix adhesion to regulation of protease activity. Increases in urokinase receptor expression known to be associated with cellular activation and malignant transformation could modulate cellular trafficking and function by promoting attachment to vitronectin.

Citing Articles

Recruitment of Vitronectin by Bacterial Pathogens: A Comprehensive Overview.

Pellegrini A, Pietrocola G Microorganisms. 2024; 12(7).

PMID: 39065153 PMC: 11278874. DOI: 10.3390/microorganisms12071385.


High-throughput optofluidic screening of single B cells identifies novel cross-reactive antibodies as inhibitors of uPAR with antibody-dependent effector functions.

Lourenco A, Chuo S, Bohn M, Hann B, Khan S, Yevalekar N MAbs. 2023; 15(1):2184197.

PMID: 36859773 PMC: 9988344. DOI: 10.1080/19420862.2023.2184197.


Biological Role of the Intercellular Transfer of Glycosylphosphatidylinositol-Anchored Proteins: Stimulation of Lipid and Glycogen Synthesis.

Muller G, Muller T Int J Mol Sci. 2022; 23(13).

PMID: 35806423 PMC: 9267055. DOI: 10.3390/ijms23137418.


suPAR to Risk-Stratify Patients With Malaria.

Stefanova V, Crowley V, Weckman A, Kain K Front Immunol. 2022; 13:931321.

PMID: 35757694 PMC: 9226448. DOI: 10.3389/fimmu.2022.931321.


Therapeutic strategies targeting uPAR potentiate anti-PD-1 efficacy in diffuse-type gastric cancer.

Qin L, Wang L, Zhang J, Zhou H, Yang Z, Wang Y Sci Adv. 2022; 8(21):eabn3774.

PMID: 35613265 PMC: 9132454. DOI: 10.1126/sciadv.abn3774.